MAPT and Alzheimer disease: The sicircNF1-419-AAV injected animals were slightly inhibited (Figure 6A), while AD marker proteins such as Tau, p-Tau, Aβ A4, APOE, and BACE1 were inhibited (p < 0.05, Figure 6B and Supplementary Figure 6), and the senescence-associated biomarkers p21 and p35 were improved (p < 0.05, Figure 6B and Figure 6) after treatment with circNF1-419-OV-AAV for 2 months.